A DNA vaccine for Andes virus has shown promising results in phase 1 trials, with over 80% of participants producing neutralizing antibodies.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Hantavirus Vaccines and Treatments Are in the Pipeline - The New York Times
80% % Participants with neutralizing antibodies
Phase 1 Trial phase
DNA Vaccine Vaccine type